• Explore /
  • Poster
  • / CAIRE: A basket multicenter open-label phase 2 study evaluating the EZH2 inhibitor tazemetostat in combination with durvalumab in patients with advanced solid tumors.

CAIRE: A basket multicenter open-label phase 2 study evaluating the EZH2 inhibitor tazemetostat in combination with durvalumab in patients with advanced solid tumors.

Abstract Poster

Authors

null

Antoine Italiano

Institut Bergonié, Bordeaux, France

Antoine Italiano , Nicolas Isambert , Jean-Philippe Metges , Maud Toulmonde , Sophie Cousin , Simon Pernot , Mariella Spalato , Thomas Grellety , Celine Auzanneau , Barbara Lortal , Michèle Kind , François Le Loarer , Sabrina Sellan-Albert , Carine A. Bellera

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Other Checkpoint Inhibitors (Non-PD1/PDL1, Monotherapy, or Combination)

Clinical Trial Registration Number

NCT04705818

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS2703)

DOI

10.1200/JCO.2022.40.16_suppl.TPS2703

Abstract #

TPS2703

Poster Bd #

339a

Abstract Disclosures

Similar Posters

First Author: Anthony B. El-Khoueiry

First Author: Viktor Grünwald

First Author: Maud Toulmonde

First Author: Lu Si